Overview

A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

Status:
Completed

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine the safety and efficacy of two dosing regimens of daclizumab in simultaneous kidney/pancreas transplant recipients.

Phase:

Phase 4

Details

Lead Sponsor:

University of Cincinnati

Collaborators:

Roche Pharma AG
University of Tennessee

Treatments:

Daclizumab
Immunoglobulin G
Mycophenolate mofetil
Mycophenolic Acid
Pancreatin
Pancrelipase
Tacrolimus